Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging

Prostate

Volumn 67, Issue 1, 2007, Pages 107-114

  Yamamoto, Hamilto ^a   Bonfil, R Daniel ^a   Wiesner, Christoph ^a   Nabha, Sanaa ^a   Dong, Zhong ^a   Meng, Hong ^a   Saliganan, Allen ^a   Sabbota, Aaron ^a   Chinni, Sreenivasa R ^a   Cher, Michael L ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone metastasis; Docetaxel; Green fluorescent protein; Prostate cancer

Indexed keywords

DOCETAXEL; GREEN FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FLUORESCENCE; FLUOROMETRY; HISTOLOGY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RADIOGRAPHY; SCID MOUSE; TUMOR VOLUME;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; SPECTROMETRY, X-RAY EMISSION;

EID: 33845775659     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20506     Document Type: Article

References (20)

1. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004;6(2):185-195.
2. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 2005;85(11):1392-1404.
3. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 1998;77(6):887-894.
4. Nemeth JA, Harb JF, Barroso U Jr., He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999;59(8):1987-1993.
5. Soos G, Jones RF, Haas GP, Wang CY. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse. Anticancer Res 1997;17(6D):4253-4258.
6. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 2002;52(1):20-33.
7. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH. Animal models of bone metastasis. Cancer 2003;97(3 Suppl): 748-757.
8. Cher ML. Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol 2001;11(5):483-488.
9. Fizazi K, Navone NM. [Preclinical models of prostate cancer]. Bull Cancer 2005;92(2):129-141.
10. Wetterwald A, van der Pluijm G, Que I, Sijmons B, Buijs J, Karperien M, Lowik CW, Gautschi E, Thalmann GN, Cecchini MG. Optical imaging of cancer metastasis to bone marrow: A mouse model of minimal residual disease. Am J Pathol 2002; 160(3):1143-1153.
11. Paris S, Sesboue R. Metastasis models: The green fluorescent revolution? Carcinogenesis 2004;25(12):2285-2292.
12. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: Androgen- independence and osseous metastasis. Prostate 2000;44(2):91-103.
13. O'Connor KL, Culp LA. Quantitation of two histochemical markers in the same extract using chemiluminescent substrates. Biotechniques 1994;17(3):502-509.
14. Zhang L, Hellstrom KE, Chen L. Luciferase activity as a marker of tumor burden and as an indicator of tumor response to antineoplastic therapy in vivo. Clin Exp Metastasis 1994;12(2): 87-92.
15. Mattano LA, Jr., Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 1992;52(17):4701-4705.
16. Rubio N, Villacampa MM, El Hilali N, Blanco J. Metastatic burden in nude mice organs measured using prostate tumor PC-3 cells expressing the luciferase gene as a quantifiable tumor cell marker. Prostate 2000;44(2):133-143.
17. Burton DW, Geller J, Yang M, Jiang P, Barken I, Hastings RH, Hoffman RM, Deftos LJ. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. Prostate 2005;62(3):275-281.
18. Kalikin LM, Schneider A, Thakur MA, Fridman Y, Griffin LB, Dunn RL, Rosol TJ, Shah RB, Rehemtulla A, McCauley LK, Pienta KJ. In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther 2003;2(6):656-660.
19. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005; 146(4):1727-1736.
20. Hensley H, Pollack A. In vivo visualization of metastatic prostate cancer. Cancer Biol Ther 2003;2(6):661-662.